https://xintela.se/mfn_news/xintelas-kliniska-studie-med-xstem-for-knaartros-fortskrider-val/ 2025-11-20T16:31:47+00:00 https://xintela.se/en/mfn_news/xintelas-stem-cell-product-xstem-has-been-assessed-as-safe-at-all-dose-levels-in-knee-osteoarthritis-clinical-study/ 2025-11-20T16:31:46+00:00 https://xintela.se/mfn_news/xintelas-stamcellsprodukt-xstem-har-bedomts-saker-pa-samtliga-dosnivaer-i-den-kliniska-studien-for-knaartros/ 2025-11-20T16:31:46+00:00 https://xintela.se/en/mfn_news/xintela-ab-interim-report-january-june-2023/ 2025-11-20T16:31:46+00:00 https://xintela.se/mfn_news/xintela-ab-delarsrapport-januari-juni-2023/ 2025-11-20T16:31:46+00:00 https://xintela.se/en/mfn_news/xintela-gets-product-patent-in-usa-for-chondrocyte-based-products/ 2025-11-20T16:31:46+00:00 https://xintela.se/mfn_news/xintela-erhaller-godkant-produktpatent-i-usa-for-broskcellsbaserade-produkter/ 2025-11-20T16:31:46+00:00 https://xintela.se/mfn_news/xintela-offentliggor-utfall-i-foretradesemissionen/ 2025-11-20T16:31:46+00:00 https://xintela.se/en/mfn_news/xintela-completes-xstem-dosing-at-third-and-final-dose-level-in-knee-osteoarthritis-clinical-study/ 2025-11-20T16:31:46+00:00 https://xintela.se/mfn_news/xintela-har-slutfort-doseringen-pa-tredje-och-sista-dosnivan-av-xstem-i-den-kliniska-studien-for-knaartros/ 2025-11-20T16:31:46+00:00 https://xintela.se/mfn_news/xintela-forlanger-teckningsperioden-i-den-pagaende-foretradesemissionen-av-units/ 2025-11-20T16:31:46+00:00 https://xintela.se/en/mfn_news/xintela-ab-interim-report-january-september-2023/ 2025-11-20T16:31:45+00:00 https://xintela.se/mfn_news/xintela-ab-delarsrapport-januari-september-2023/ 2025-11-20T16:31:45+00:00 https://xintela.se/mfn_news/xintela-publicerar-effektresultat-med-eqstem-fran-preklinisk-artrosstudie-pa-hastar/ 2025-11-20T16:31:45+00:00 https://xintela.se/mfn_news/xintela-offentliggor-utfall-for-utnyttjandet-av-teckningsoptioner-av-serie-to3-4/ 2025-11-20T16:31:45+00:00 https://xintela.se/en/mfn_news/vastra-hamnen-corporate-finance-initiates-coverage-of-xintela/ 2025-11-20T16:31:45+00:00 https://xintela.se/mfn_news/vastra-hamnen-corporate-finance-inleder-analysbevakning-av-xintela/ 2025-11-20T16:31:45+00:00 https://xintela.se/mfn_news/flerie-invest-samt-delar-av-styrelsen-och-ledningen-i-xintela-har-utnyttjat-teckningsoptioner-av-serie-to3/ 2025-11-20T16:31:45+00:00 https://xintela.se/en/mfn_news/xintela-changes-certified-adviser-to-carnegie-investment-bank-ab-publ/ 2025-11-20T16:31:45+00:00 https://xintela.se/mfn_news/xintela-byter-certified-adviser-till-carnegie-investment-bank-ab-publ/ 2025-11-20T16:31:45+00:00 https://xintela.se/mfn_news/den-forsta-utnyttjandeperioden-for-xintelas-teckningsoptioner-av-serie-to3-inleds-den-25-november-2023/ 2025-11-20T16:31:45+00:00 https://xintela.se/mfn_news/xintela-ab-bokslutskommunike-2023/ 2025-11-20T16:31:44+00:00 https://xintela.se/en/mfn_news/xintela-appoints-lucienne-vonk-as-chief-scientific-officer/ 2025-11-20T16:31:44+00:00 https://xintela.se/mfn_news/xintela-utser-lucienne-vonk-till-chief-scientific-officer/ 2025-11-20T16:31:44+00:00 https://xintela.se/en/mfn_news/xintela-newsletter-no-1-2024/ 2025-11-20T16:31:44+00:00 https://xintela.se/mfn_news/nyhetsbrev-fran-xintela-nr-1-2024/ 2025-11-20T16:31:44+00:00 https://xintela.se/en/mfn_news/first-patient-dosed-in-xintelas-clinical-study-on-difficult-to-heal-leg-ulcers/ 2025-11-20T16:31:44+00:00 https://xintela.se/mfn_news/forsta-patienten-doserad-i-xintelas-kliniska-studie-pa-svarlakta-bensar/ 2025-11-20T16:31:44+00:00 https://xintela.se/en/mfn_news/xintela-publishes-efficacy-results-with-eqstem-from-preclinical-equine-oa-study/ 2025-11-20T16:31:44+00:00 https://xintela.se/mfn_news/xintela-ab-publicerar-arsredovisning-for-2023/ 2025-11-20T16:31:44+00:00 https://xintela.se/mfn_news/kallelse-till-arsstamma-i-xintela-ab-publ-2/ 2025-11-20T16:31:44+00:00 https://xintela.se/en/mfn_news/xintela-ab-year-end-report-2023/ 2025-11-20T16:31:44+00:00 https://xintela.se/mfn_news/xintela-forlanger-klinisk-studie-med-xstem-pa-knaartrospatienter/ 2025-11-20T16:31:43+00:00 https://xintela.se/mfn_news/xintela-offentliggor-utfall-for-utnyttjandet-av-teckningsoptioner-av-serie-to3-3/ 2025-11-20T16:31:43+00:00 https://xintela.se/mfn_news/den-andra-utnyttjandeperioden-for-xintelas-teckningsoptioner-av-serie-to3-inleds-den-26-maj-2024/ 2025-11-20T16:31:43+00:00 https://xintela.se/en/mfn_news/xintela-ab-interim-report-january-march-2024/ 2025-11-20T16:31:43+00:00 https://xintela.se/mfn_news/xintela-ab-delarsrapport-januari-mars-2024/ 2025-11-20T16:31:43+00:00 https://xintela.se/en/mfn_news/xintela-and-eqgen-biomedical-to-collaborate-to-develop-eqstem-stem-cell-treatment-for-horses/ 2025-11-20T16:31:43+00:00 https://xintela.se/mfn_news/xintela-och-eqgen-biomedical-avser-samarbeta-for-utveckling-av-stamcellsprodukten-eqstem-for-behandling-av-hastar/ 2025-11-20T16:31:43+00:00 https://xintela.se/mfn_news/kommunike-fran-arsstamma-i-xintela-ab-publ-2/ 2025-11-20T16:31:43+00:00 https://xintela.se/en/mfn_news/xintela-ab-publishes-annual-report-2023/ 2025-11-20T16:31:43+00:00 https://xintela.se/en/mfn_news/xintela-extends-clinical-study-with-xstem-on-knee-osteoarthritis-patients/ 2025-11-20T16:31:43+00:00 https://xintela.se/mfn_news/xintela-offentliggor-utfall-for-utnyttjandet-av-teckningsoptioner-av-serie-to3-2/ 2025-11-20T16:31:42+00:00 https://xintela.se/mfn_news/den-tredje-utnyttjandeperioden-for-xintelas-teckningsoptioner-av-serie-to3-inleds-den-25-november-2024/ 2025-11-20T16:31:42+00:00 https://xintela.se/en/mfn_news/xintela-ab-interim-report-january-september-2024/ 2025-11-20T16:31:42+00:00 https://xintela.se/mfn_news/xintela-ab-delarsrapport-januari-september-2024/ 2025-11-20T16:31:42+00:00 https://xintela.se/en/mfn_news/xintelas-main-owner-flerie-undertakes-to-exercise-warrants-to3-of-approximately-sek-28-million-and-provides-a-bridge-loan-of-sek-9-million/ 2025-11-20T16:31:42+00:00 https://xintela.se/mfn_news/xintelas-huvudagare-flerie-atar-sig-att-utnyttja-teckningsoptioner-to3-om-cirka-28-miljoner-kronor-samt-lamnar-brygglan-om-9-miljoner-kronor/ 2025-11-20T16:31:42+00:00 https://xintela.se/en/mfn_news/xintela-presents-new-preclinical-results-of-xstem-treatment-on-would-healing-and-skin-regeneration-at-cell-therapy-conference/ 2025-11-20T16:31:42+00:00 https://xintela.se/mfn_news/xintela-presenterar-nya-prekliniska-resultat-med-xstem-pa-sarlakning-och-regenerering-av-hud-pa-cellterapikonferens/ 2025-11-20T16:31:42+00:00 https://xintela.se/mfn_news/xintela-ab-delarsrapport-januari-juni-2024/ 2025-11-20T16:31:42+00:00 https://xintela.se/en/mfn_news/xintela-ab-interim-report-january-june-2024/ 2025-11-20T16:31:42+00:00 https://xintela.se/en/mfn_news/xintela-signs-agreement-with-region-ostergotland-for-gmp-process-development-of-cell-therapy-for-burn-patients/ 2025-11-20T16:31:42+00:00 https://xintela.se/mfn_news/xintela-tecknar-uppdragsavtal-med-region-ostergotland-for-gmp-reglerad-processutveckling-av-cellterapi-for-brannskadepatienter/ 2025-11-20T16:31:42+00:00 https://xintela.se/mfn_news/xintela-och-eqgen-biomedical-tecknar-samarbets-och-licensavtal-for-stamcellsprodukter-inom-veterinarmedicin/ 2025-11-20T16:31:41+00:00 https://xintela.se/en/mfn_news/xintela-and-eqgen-biomedical-sign-collaboration-and-license-agreement-for-veterinarian-stem-cell-products/ 2025-11-20T16:31:41+00:00 https://xintela.se/en/mfn_news/xintela-decreases-patient-number-in-xstem-clinical-study-in-difficult-to-heal-venous-leg-ulcers/ 2025-11-20T16:31:41+00:00 https://xintela.se/mfn_news/xintela-minskar-antalet-patienter-i-klinisk-studie-med-xstem-pa-svarlakta-venosa-bensar/ 2025-11-20T16:31:41+00:00 https://xintela.se/en/mfn_news/xintelas-stem-cell-product-xstem-shows-safety-and-positive-efficacy-results-in-knee-osteoarthritis-clinical-study/ 2025-11-20T16:31:41+00:00 https://xintela.se/mfn_news/xintelas-stamcellsprodukt-xstem-visar-sakerhet-och-positiva-effektresultat-i-klinisk-studie-pa-knaartros/ 2025-11-20T16:31:41+00:00 https://xintela.se/mfn_news/xintela-ab-bokslutskommunike-2024/ 2025-11-20T16:31:41+00:00 https://xintela.se/en/mfn_news/xintela-ab-year-end-report-2024/ 2025-11-20T16:31:41+00:00 https://xintela.se/en/mfn_news/xintela-ab-interim-report-january-march-2025/ 2025-11-20T16:31:40+00:00 https://xintela.se/mfn_news/xintela-ab-delarsrapport-januari-mars-2025/ 2025-11-20T16:31:40+00:00 https://xintela.se/mfn_news/xintela-ab-publicerar-arsredovisning-for-2024/ 2025-11-20T16:31:40+00:00 https://xintela.se/en/mfn_news/xintela-ab-publishes-annual-report-2024/ 2025-11-20T16:31:40+00:00 https://xintela.se/mfn_news/kallelse-till-arsstamma-i-xintela-ab-publ/ 2025-11-20T16:31:40+00:00 https://xintela.se/mfn_news/kommunike-fran-arsstamma-i-xintela-ab-publ/ 2025-11-20T16:31:40+00:00 https://xintela.se/mfn_news/xintela-offentliggor-utfall-for-utnyttjandet-av-teckningsoptioner-av-serie-to3/ 2025-11-20T16:31:40+00:00 https://xintela.se/mfn_news/xintelas-erbjudande-att-teckna-optioner-av-serie-to3-pagar-till-och-med-5-juni-2025/ 2025-11-20T16:31:40+00:00 https://xintela.se/mfn_news/xintelas-sista-erbjudande-att-teckna-optioner-av-serie-to3-inleds-idag-den-26-maj-2025/ 2025-11-20T16:31:40+00:00 https://xintela.se/mfn_news/xintelas-stamcellsprodukt-xstem-visar-sakerhet-och-bestaende-positiva-effektresultat-tva-ar-efter-behandling-i-klinisk-studie-pa-knaartros/ 2025-11-20T16:31:39+00:00 https://xintela.se/en/mfn_news/xintelas-stem-cell-product-xstem-shows-safety-and-sustained-positive-efficacy-results-two-years-after-treatment-in-knee-osteoarthritis-clinical-study/ 2025-11-20T16:31:39+00:00 https://xintela.se/mfn_news/xintela-ab-halvarsrapport-januari-juni-2025/ 2025-11-20T16:31:39+00:00 https://xintela.se/en/mfn_news/xintela-ab-interim-report-january-june-2025/ 2025-11-20T16:31:39+00:00 https://xintela.se/mfn_news/xintela-starker-ledningen-med-peter-ekolind-som-coo-vp-commercial-manufacturing/ 2025-11-20T16:31:39+00:00 https://xintela.se/en/mfn_news/xintela-strengthens-management-team-with-peter-ekolind-as-coo-vp-commercial-manufacturing/ 2025-11-20T16:31:39+00:00 https://xintela.se/en/mfn_news/xintela-completes-clinical-study-with-xstem-in-knee-osteoarthritis/ 2025-11-20T16:31:39+00:00 https://xintela.se/mfn_news/xintela-slutfor-klinisk-knaartrosstudie-med-xstem/ 2025-11-20T16:31:39+00:00 https://xintela.se/mfn_news/xintela-ab-byter-certified-adviser-till-tapper-partners-ab/ 2025-11-20T16:31:39+00:00 https://xintela.se/en/mfn_news/xintela-ab-changes-certified-adviser-to-tapper-partners-ab/ 2025-11-20T16:31:39+00:00 https://xintela.se/mfn_news/xintela-tillkannager-samarbete-mellan-dotterbolaget-targinta-och-msk-therapeutics-accelerator/ 2025-11-20T16:31:38+00:00 https://xintela.se/en/mfn_news/xintela-announces-subsidiary-targinta-collaboration-with-msk-therapeutics-accelerator/ 2025-11-20T16:31:38+00:00